INNOVIVA, INC. Class of Warrant or Right, Outstanding
INNOVIVA, INC. (INVA) had Class of Warrant or Right, Outstanding of 0 shares as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Other Liabilities
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2026-02-25
- 2025-12-31: Class of Warrant or Right, Outstanding 0.00 shares.
- 2025-09-30: Class of Warrant or Right, Outstanding 0.00 shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2025-12-31 | 0.00 shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |